Rydapt
| Chemical Name | midostaurin |
| Dosage Form | Capsule (oral; 25 mg) |
| Drug Class | Kinase inhibitors |
| System | Blood |
| Company | Novartis |
| Approval Year | 2017 |
Indication
- To treat newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive in adults.
- To treat aggressive systemic mastocytosis in adults.
- To treat systemic mastocytosis with associated hematological neoplasm in adults.
- To treat mast cell leukemia in adults.